|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 45/06 | (2006.01) |
| A61K 9/20 | (2006.01) | ||
| A61K 31/166 | (2006.01) | ||
| A61K 31/44 | (2006.01) | ||
| A61P 11/06 | (2006.01) |
| (11) | Number of the document | 2258394 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10173234.5 |
| Date of filing the European patent application | 2003-02-19 | |
| (97) | Date of publication of the European application | 2010-12-08 |
| (45) | Date of publication and mention of the grant of the patent | 2013-05-15 |
| (46) | Date of publication of the claims translation | 2013-09-25 |
| (30) | Number | Date | Country code |
| 10207160 | 2002-02-20 | DE | |
| 02003811 | 2002-02-20 | EP |
| (72) |
Dietrich, Rango, DE
Ney, Hartmut, DE
Eistetter, Klaus, DE
|
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Geriamoji vaisto forma, apimanti PDE 4 inhibitorių kaip aktyvųjį ingredientą ir polivinilpirolidoną kaip pagalbinę medžiagą |
| Oral dosage form comprising a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
| Payment date | Validity (years) | Amount | |
| 2022-01-19 | 20 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2022-07-28 |